









Markets
/
Stocks
/
nasdaq-vero
/

Venus Concept Inc

VERO

2.110USD

0.000

Close 11/04, 16:00（ET）Quotes delayed by 15 min

3.92MMarket Cap

LossP/E TTM



Venus Concept Inc

2.110

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Venus Concept Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Venus Concept Inc's Score

Industry at a Glance

Industry Ranking

146 / 210

Overall Ranking

351 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Hold

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Venus Concept Inc Highlights

StrengthsRisks

Venus Concept Inc. is a global medical technology company. The Company develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and 10 direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.

Growing

The company is in a growing phase, with the latest annual income totaling USD 64.83M.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 256.21K shares, increasing 19.61% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.97.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.52, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 15.69M, representing a year-over-year decrease of 5.37%, while its net profit experienced a year-over-year decrease of 41.25%.

Score

Industry at a Glance

Previous score

6.52

Change



Financials

3.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.49

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

Venus Concept Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.60, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.05, which is -55.09% below the recent high of -0.02 and -12105.57% above the recent low of -6.36.

Score

Industry at a Glance

Previous score

7.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Hold

Current Rating

0.000

Target Price

0.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Venus Concept Inc

VERO

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 3.51, which is lower than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 2.58 and the support level at 1.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.06

Change

0.45

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.035

Sell

RSI(14)

38.715

Neutral

STOCH(KDJ)(9,3,3)

21.955

Neutral

ATR(14)

0.124

Low Volatility

CCI(14)

-96.865

Neutral

Williams %R

89.583

Oversold

TRIX(12,20)

-0.409

Sell

StochRSI(14)

21.693

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.130

Sell

MA10

2.161

Sell

MA20

2.276

Sell

MA50

2.296

Sell

MA100

2.389

Sell

MA200

2.730

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 13.78%, representing a quarter-over-quarter decrease of 15.57%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Orca Capital GmbH

101.75K

EW Healthcare Partners

99.02K

+0.00%

HealthQuest Capital Management, L.P

41.19K

Madryn Asset Management, LP

10.19K

De Silva (Rajiv)

7.58K

Tower Research Capital LLC

3.92K

+120.03%

Hollmig (Stanley Tyler)

1.76K

Gunhus (Kirk)

1.64K

Varghese (Hemanth Jacob)

1.52K

+0.07%

Della Penna (Domenic)

918.00

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.84, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.